Novavax said that a preliminary analysis showed that its vaccine against the Covid-19 is 89.3% effective in an experiment conducted in Britain, and the company also said, it provides almost the same level of protection from the most contagious strain of Corona virus.

A trial of the vaccine in South Africa showed, Where a new type of strain virus is spread, with 60% effectiveness among people who have not been infected with HIV that causes AIDS.

- Novavax shares jumped by 34% in after hours trading, following the announcement of the test results on the same day that the United States recorded its first case of the South African strain.

- Novavax is already storing the vaccine at six manufacturing sites. It said it expects a total of 8 factories in 7 countries to produce an average of 2 billion doses per year, including doses from the Indian Serum Institute for Vaccine

- The Novavax company said in a conference call that these are interim data, and its top officials have expected 2 to 3 months to pass before they are ready to apply for a license from regulators.

- The British experiment was conducted on 15,000 people between the ages of 18 and 84 years, and it is expected that they will be used to apply for the use of the vaccine in Britain, the European Union countries, and others.

- Approval of the Novavax vaccine will be very welcome in Europe, which is struggling to obtain other supplies of vaccines after it received less than hoped quantities of the vaccines, "Pfizer - BioNTech" and "AstraZene

SOURCE : SAUDI EXPATRIATES

Follow us on Facebook and Instagram

For Saudi Arabia Business Directory 
For Saudi Arabia Latest News 
For Saudi Arabia Daily Exchange Rates 
For Saudi Arabia Daily Gold Rates
For Saudi Arabia Latest Offers